Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.

Wu J, Dombi E, Jousma E, Scott Dunn R, Lindquist D, Schnell BM, Kim MO, Kim A, Widemann BC, Cripe TP, Ratner N.

Pediatr Blood Cancer. 2012 Feb;58(2):173-80. doi: 10.1002/pbc.23015.

2.
3.

Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Ferguson MJ, Rhodes SD, Jiang L, Li X, Yuan J, Yang X, Zhang S, Vakili ST, Territo P, Hutchins G, Yang FC, Ingram DA, Clapp DW, Chen S.

Pediatr Blood Cancer. 2016 Feb;63(2):206-13. doi: 10.1002/pbc.25763.

4.

Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.

Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL, Powell NM, Collins MH, Rizvi T, Moertel CL, Ratner N, Largaespada DA.

Oncotarget. 2014 Mar 30;5(6):1502-14.

5.

Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJ.

Pediatr Blood Cancer. 2014 Jun;61(6):982-6.

PMID:
24851266
6.

Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells.

Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, Stemmer-Rachamimov AO, Cancelas JA, Ratner N.

Cancer Cell. 2008 Feb;13(2):105-16. doi: 10.1016/j.ccr.2007.12.027.

7.

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.

Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Reddy A, Korf B, Widemann BC.

Pediatr Blood Cancer. 2013 Mar;60(3):396-401. doi: 10.1002/pbc.24281.

PMID:
22961690
8.

Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.

Spirli C, Morell CM, Locatelli L, Okolicsanyi S, Ferrero C, Kim AK, Fabris L, Fiorotto R, Strazzabosco M.

Hepatology. 2012 Dec;56(6):2363-74. doi: 10.1002/hep.25872.

9.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057.

10.

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW.

Lancet Oncol. 2012 Dec;13(12):1218-24. doi: 10.1016/S1470-2045(12)70414-X.

PMID:
23099009
11.

Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.

Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, Ratner N.

Acta Neuropathol. 2013 Jan;125(1):159-68. doi: 10.1007/s00401-012-1056-7.

12.

Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, Yang S, Pounds S, Fan Y, Calabrese C, Rehg JE, Campana D, Rubnitz JE, Baker SD.

J Natl Cancer Inst. 2011 Jun 8;103(11):893-905. doi: 10.1093/jnci/djr107.

13.

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR.

Cancer Res. 2007 Mar 15;67(6):2408-13.

14.

Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.

Jousma E, Rizvi TA, Wu J, Janhofer D, Dombi E, Dunn RS, Kim MO, Masters AR, Jones DR, Cripe TP, Ratner N.

Pediatr Blood Cancer. 2015 Oct;62(10):1709-16. doi: 10.1002/pbc.25546.

15.

Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Staser K, Yang FC, Clapp DW.

Annu Rev Pathol. 2012;7:469-95. doi: 10.1146/annurev-pathol-011811-132441. Review.

16.

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ.

Neuro Oncol. 2015 Apr;17(4):596-603. doi: 10.1093/neuonc/nou235. Erratum in: Neuro Oncol. 2015 Jun;17(6):905.

17.

Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.

Hegedus B, Banerjee D, Yeh TH, Rothermich S, Perry A, Rubin JB, Garbow JR, Gutmann DH.

Cancer Res. 2008 Mar 1;68(5):1520-8. doi: 10.1158/0008-5472.CAN-07-5916.

18.

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ.

Cancer Chemother Pharmacol. 2013 May;71(5):1219-29. doi: 10.1007/s00280-013-2116-y.

19.

Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1.

Jett K, Nguyen R, Arman D, Birch P, Chohan H, Farschtschi S, Fuensterer C, Kluwe L, Friedman JM, Mautner VF.

Am J Med Genet A. 2015 Jul;167(7):1518-24. doi: 10.1002/ajmg.a.37068.

PMID:
25900062
20.

Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma.

Chen Z, Liu C, Patel AJ, Liao CP, Wang Y, Le LQ.

Cancer Cell. 2014 Nov 10;26(5):695-706. doi: 10.1016/j.ccell.2014.09.009.

Items per page

Supplemental Content

Support Center